Literature DB >> 32130823

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply.

John J V McMurray1, Kieran F Docherty1, Pardeep S Jhund1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32130823     DOI： 10.1056/NEJMc1917241

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

1.  First experience with sodium-glucose co-transporter 2 inhibitors in Polish patients with cardiovascular diseases.

Authors:  Ewa Dziewięcka; Mateusz Winiarczyk; Matylda Gliniak; Monika Kaciczak; Sylwia Wiśniowska-Śmiałek; Aleksandra Karabinowska; Katarzyna Holcman; Magdalena Kostkiewicz; Marta Hlawaty; Agata Leśniak-Sobelga; Piotr Podolec; Paweł Rubiś
Journal:  Cardiol J       Date:  2020-08-13       Impact factor: 2.737

2.  A Heartwarming Role of the Proximal Tubules.

Authors:  Michael L Granda; Bryan Kestenbaum
Journal:  Clin J Am Soc Nephrol       Date:  2022-02       Impact factor: 8.237

3.  Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.

Authors:  Gregory D Lewis; Adriaan A Voors; Alain Cohen-Solal; Marco Metra; David J Whellan; Justin A Ezekowitz; Michael Böhm; John R Teerlink; Kieran F Docherty; Renato D Lopes; Punag H Divanji; Stephen B Heitner; Stuart Kupfer; Fady I Malik; Lisa Meng; Amy Wohltman; G Michael Felker
Journal:  JAMA       Date:  2022-07-19       Impact factor: 157.335

Review 4.  SGLT2-Inhibitors on HFpEF Patients. Role of Ejection Fraction.

Authors:  Juan Antonio Requena-Ibanez; Carlos G Santos-Gallego; M Urooj Zafar; Juan J Badimon
Journal:  Cardiovasc Drugs Ther       Date:  2022-08-03       Impact factor: 3.947

5.  Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan.

Authors:  Ataru Igarashi; Keiko Maruyama-Sakurai; Anna Kubota; Hiroki Akiyama; Toshitaka Yajima; Shun Kohsaka; Hiroaki Miyata
Journal:  Diabetes Ther       Date:  2022-06-16       Impact factor: 3.595

6.  Dapagliflozin Attenuates Myocardial Fibrosis by Inhibiting the TGF-β1/Smad Signaling Pathway in a Normoglycemic Rabbit Model of Chronic Heart Failure.

Authors:  Xuefeng Chen; Qian Yang; Wenlou Bai; Wenjing Yao; Litian Liu; Yuanyuan Xing; Cunliang Meng; Peng Qi; Yi Dang; Xiaoyong Qi
Journal:  Front Pharmacol       Date:  2022-05-13       Impact factor: 5.988

7.  The role of diabetes in cardiomyopathies of different etiologies-Characteristics and 1-year follow-up results of the EVITA-HF registry.

Authors:  Christine Meindl; Matthias Hochadel; Lutz Frankenstein; Oliver Bruder; Matthias Pauschinger; Rainer Hambrecht; Wolfgang von Scheidt; Otmar Pfister; Andreas Hartmann; Lars S Maier; Jochen Senges; Bernhard Unsöld
Journal:  PLoS One       Date:  2020-06-11       Impact factor: 3.240

8.  Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes.

Authors:  Navya Varshney; Sarah J Billups; Joseph J Saseen; Cy W Fixen
Journal:  Ther Adv Drug Saf       Date:  2021-03-29

9.  Development and Validation of a Novel Nomogram to Predict Improved Left Ventricular Ejection Fraction in Patients With Heart Failure After Successful Percutaneous Coronary Intervention for Chronic Total Occlusion.

Authors:  Lulu Yang; Huan Li; Guangli Guo; Jiaqi Du; Zhengyang Hao; Lingyao Kong; Huiting Shi; Xiaofang Wang; Yanzhou Zhang
Journal:  Front Cardiovasc Med       Date:  2022-04-14

10.  Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.

Authors:  Kåre I Birkeland; Johan Bodegard; Amitava Banerjee; Dae Jung Kim; Anna Norhammar; Jan W Eriksson; Marcus Thuresson; Suguru Okami; Kyoung Hwa Ha; Nils Kossack; Jil Billy Mamza; Ruiqi Zhang; Toshitaka Yajima; Issei Komuro; Takashi Kadowaki
Journal:  Diabetes Obes Metab       Date:  2020-09-28       Impact factor: 6.577
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.